Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

References

• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019: ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). 2019 Jun 17 [accessed 2019 Aug 21].
   Google Scholar
• Word Health Organization, Human papillomavirus (HPV) and cervical cancer. Geneva: 2019. Jan 24. [accessed: 2019 Aug 21. https://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
   Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716. PMID: 28369882
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled tria. Lancet. 2007;369(9580):2161–70. PMID: 17602732. doi:10.1016/s0140-6736(07)60946-5.
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27. PMID: 17494925. doi:10.1056/NEJMoa061741.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr, Ngan Y, Petersen LK, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. Engl N, Med J. 2015; 3728: 711–23. 10.1056/NEJMoa1405044. PMID: 25693011.
   PubMed Web of Science ®Google Scholar
• Word Health Organization. Vaccines in National Immunization Programme, Slides on introduction status of selected vaccines. Geneva: 2020. Jan 30 [accessed: 2020 Feb 15. https://www.who.int/immunization/monitoring_surveillance/data/en/
   Google Scholar
• The Global Alliance for Vaccines and Immunisation. Hpv Supply and Procurement Roadmap. Geneva: 2017. Dec 20. [accessed: 2019 Aug 21. https://www.gavi.org/sites/default/files/document/hpvsupplyandrocurementroadmappdf.pdf
   Google Scholar
• Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016;63(4):519–27. PMID: 27230391. doi:10.1093/cid/ciw354.
   PubMed Web of Science ®Google Scholar
• Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee JH, Du R, Robertson M, Norville S, et al. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. JAMA Oncol. 2017;3(6):833–37. PMID: 27685805. doi:10.1001/jamaoncol.2016.3609.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. PMID: 31255301. doi:10.1016/s0140-6736(19)30298-3.
   PubMed Web of Science ®Google Scholar
• Word Health Organization. WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. Geneva: 2018. May 19 [accessed: 2019 Dec 19]. https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/
   Google Scholar
• Word Health Organization. Immunisation Agenda 2030 A Global Strategy To Leave No One Behind. Geneva: [accessed: 2019 Dec 19]. https://www.who.int/immunization/immunization_agenda_2030/en/
   Google Scholar
• Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2019; Apr 23. [accessed 2019 Aug 21]. doi: 10.1093/jnci/djz074. PMID: 31086947.
   PubMedGoogle Scholar
• Su YY, Lin BZ, Zhao H, Li J, Lin ZJ, Qiao YL, Wei LH, Hu YM, Li RC, Zhuang SJ, et al. Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial. Hum Vaccin Immunother. 2019;1–9. doi:10.1080/21645515.2019.1691413. PMID: 31770068.
   PubMed Web of Science ®Google Scholar
• Hu Y, Guo M, Li C, Chu K, He W, Zhang J, Gu J, Li J, Zhao H, Wu X, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China Life Sci. 2019. PMID: 31231780. doi:10.1007/s11427-019-9547-7.
   Web of Science ®Google Scholar
• Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol. 2011;85(24):13253–59. doi:10.1128/JVI.06093-11. PMID: 21976653
   PubMed Web of Science ®Google Scholar
• Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, Wu T, Zhang J, Li S, Xia N. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine. 2017;35(35 Pt B)):4637–45. doi:10.1016/j.vaccine.2017.06.084. PMID: 28736197
   PubMed Web of Science ®Google Scholar
• Zhao H, Lin ZJ, Huang SJ, Li J, Liu XH, Guo M, Zhang J, Xia NS, Pan HR, Wu T, et al. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum Vaccin Immunother. 2014;10(3):740–46. PMID: 24384608. doi:10.4161/hv.27619.
   PubMed Web of Science ®Google Scholar
• Donken R, de Melker HE, Rots NY, Berbers G, Knol MJ. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine. 2015;33(12):1426–32. doi:10.1016/j.vaccine.2015.01.072. PMID: 25659273
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135–45. PMID: 17079588. doi:10.1542/peds.2006-0461.
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40(6):564–71. PMID: 17531764. doi:10.1016/j.jadohealth.2007.02.015.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis. 2009;200(2):166–71. doi:10.1086/599988. PMID: 19519255
   PubMed Web of Science ®Google Scholar
• Ferguson M, Wilkinson DE, Zhou T. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine. 2009;27(3):337–47. doi:10.1016/j.vaccine.2008.10.062. PMID: 19007840
   PubMed Web of Science ®Google Scholar
• Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4(6):425–34. doi:10.4161/hv.4.6.6912. PMID: 18948732
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. The HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):15. doi:10.4161/hv.5.10.9518.
   PubMedGoogle Scholar
• Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J. Collaborative Study Participants. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer. 2006;118(6):1508–14. doi:10.1002/ijc.21515. PMID: 16184553
   PubMed Web of Science ®Google Scholar
• Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccin. 2014;13(8):1027–38. doi:10.1586/14760584.2014.935767. PMID: 25001893
   PubMed Web of Science ®Google Scholar
• Siegrist C-A, Vaccine Immunology. 2018; p. 16-34e7.
   Google Scholar
• Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381(27):751–58. doi:10.1038/381751a0. PMID: 8657279
   PubMedGoogle Scholar
• Widdice LE, Unger ER, Panicker G, Hoagland R, Callahan ST, Jackson LA, Berry AA, Kotloff K, Frey SE, Harrison CJ, et al. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine. 2018;36(6):881–89. PMID: 29306506. doi:10.1016/j.vaccine.2017.12.042.
   PubMed Web of Science ®Google Scholar
• Esposito S, Birlutiu V, Jarcuska P, Perino A, Man SC, Vladareanu R, Meric D, Dobbelaere K, Thomas F, Descamps D. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr Infect Dis J. 2011;30(3):e49–55. doi:10.1097/INF.0b013e318206c26e. PMID: 21273939
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E, Cost G, Hand L, Hayes J, Michaels M. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health (Larchmt). 2010;19(8):1441–47. doi:10.1089/jwh.2009.1753. PMID: 20629576
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NTN, Tsu V, LaMontagne DS. Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in Vietnam. JAMA. 2011;305(14):1424–31. doi:10.1001/jama.2011.407. PMID: 21486975
   PubMed Web of Science ®Google Scholar